HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $25 to $10.
HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $25 to $10.